IQ-AI subsidiary applies to FDA for ‘breakthrough therapy’
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) told investors that its wholly owned subsidiary, Imaging Biometrics, has submitted an application to the US…
0,010€
Echtzeit-Aktienkurs IQ-AI Ltd.
Bid:
Ask:
Nachrichten zur IQ-AI Ltd. Aktie
IQ-AIs Imaging Biometrics expands distribution deal with Bayers Blackford
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has expanded its distribution agreement with artificial intelligence imaging platform...…
IQ-AI: Advancing AI for brain tumour care and clinical trials
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it is making significant strides in using artificial intelligence (AI) to improve the diagnosis and…
IQ-AI subsidiary IB installs first US system with Prism
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), a subsidiary of IQ-AI, has completed the first installation of its bundled technologies in partnership with…
IQ-AI subsidiary Imaging Biometrics expands GE partnership, adds board member
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) earlier this week announced an expanded partnership between its subsidiary, Imaging Biometrics, and GE Healthcare. The...…
IQ-AIs Imaging Biometrics extends GE partnership
Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has extended its partnership with GE HealthCare to broaden access to its...…
IQ-AI files of patent and updates on trading and clinical trial
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) has filed a provisional application with the US Patent and Trademark Office for using Gallium Maltolate as a…
IQ-AI nearing a pivotal stage in the development of cancer treatment
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it is nearing the completion of its phase I clinical trial of its IB003 cancer treatment with only…
IQ-AI approaching end of phase 1 trial of cancer treatment trial
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its Phase 1 Clinical Trial for IB003, its gallium maltolate childrens brain cancer treatment, is in…
IQ-AI approaching end of phase 1 of cancer treatment trial
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said its Phase 1 Clinical Trial for IB003, its gallium maltolate childrens brain cancer treatment, is in…
IQ-AI subsidiary receives US access programme approval for brain cancer treatment
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has received approval for an Expanded Access Program (EAP) for oral gallium maltolate…
IQ-AI Ltd says major East Coast cancer centre to use its technology
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said a US cancer centre has adopted IB Nimble for its Brain Metastases Program of Excellence. IB Nimble,…
IQ-AI boosted with second FDA rare pediatric disease designation for GaM
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) told investors that its subsidiary, Imaging Biometrics, has received a second US FDA Rare Pediatric Disease…
IQ-AI software installed by Swiss hospital group
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)s subsidiary, Imaging Biometrics, has successfully installed its advanced imaging software at Insel Gruppe AG, a hospital...…
IQ-AI subsidiary wins FDA designation for lead drug candidate
Imaging Biometrics, a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has announced that the US Food and Drug Administration (FDA) has granted…
IQ-AI shares jump as therapy offered to brain tumour patients
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the medical technology and pharmaceutical company, saw its shares pop 5% after it revealed its subsidiary…